SESSION 5: PEDIATRIC LYMPHOMAS
CURRENT STATUS AND CHALLENGES IN DIAGNOSIS OF CHILDHOOD NHL abstract
Wolfram Klapper, Kiel, DE
The study author concludes that it seems that despite tremendous progress in molecular insights into lymphoma biology, for the most frequent entities of Non-Hodgkin lymphoma in young patients the requirements for diagnosis leading to optimal patient care are vastly unaltered over the last decades.
DOSE-ADJUSTED EPOCH-RITUXIMAB OR INTENSIFIED B-NHL-BFM-TYPE THERAPY FOR PEDIATRIC PRIMARY MEDIASTINAL B-CELL LYMPHOMA abstract
F Knörr, M Zimmermann, A Attarbaschi, E Kabíčková, et al.
The study authors conclude that DA-EPOCH-R was superior to the previous chemotherapy regimens for mature B-NHL in children and adolescents with PMBCL. However, the observed improvement in EFS with intensified chemotherapy in the B 04 trial was not statistically significant.
AN OPEN-LABEL, PHASE 1/2 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN + ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE IN PAEDIATRIC PATIENTS WITH ADVANCED STAGE HODGKIN LYMPHOMA abstract
A.R.K Franklin, F. A. V Luisi, M. A Pianovski, M. A Salvino, et al.
The study authors conclude that frontline brentuximab vedotin (48 mg/m2) +AVD was well tolerated providing high rates of ORR, CR, and PET2- in paediatric patients with advanced cHL, aligning with adult efficacy and safety seen in ECHELON-1.
BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH STAGE III OR IV HODGKIN LYMPHOMA: A SUBGROUP ANALYSIS FROM THE PHASE 3 ECHELON-1 STUDY abstract
H. E Crosswell, A. S. LaCasce, N. L Bartlett, D. J Straus, et al.
The study authors conclude that consistent with the ITT population, young adults (AYAs) treated with Brentuximab vedotin + doxorubicin, vinblastine, and dacarbazine chemotherapy (A+AVD) compared to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) had a durable PFS benefit at this significant 5-year milestone. No impact on the rate of secondary malignancies and a numerically greater number of pregnancies were observed. Additionally, the majority of PN events improved or resolved over time. The authors conclude that A+AVD should be considered a treatment option for AYAs with stage III/IV cHL.
A UK POPULATION-BASED STUDY OF NON-HODGKIN LYMPHOMA IN TEENAGERS AND YOUNG ADULTS (TYA) - INCIDENCE, TREATMENT AND OUTCOMES abstract
R Carr, A Davies, B Uttenthal, M Lamb, J Fidalgo, B Carpenter
The study authors conclude that NHL in teenage and young adult patients is challenging to manage. Advanced disease and resistance to first-line treatment are common. Our findings support the treatment of these cases guided by experienced cancer centers. The detailed information gained by this national collaboration provides the evidence base for future trials and treatment strategies.